489 related articles for article (PubMed ID: 11532109)
1. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease.
Jafar TH; Stark PC; Schmid CH; Landa M; Maschio G; Marcantoni C; de Jong PE; de Zeeuw D; Shahinfar S; Ruggenenti P; Remuzzi G; Levey AS;
Kidney Int; 2001 Sep; 60(3):1131-40. PubMed ID: 11532109
[TBL] [Abstract][Full Text] [Related]
2. The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease.
Jafar TH; Stark PC; Schmid CH; Strandgaard S; Kamper AL; Maschio G; Becker G; Perrone RD; Levey AS;
Kidney Int; 2005 Jan; 67(1):265-71. PubMed ID: 15610250
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.
Jafar TH; Schmid CH; Landa M; Giatras I; Toto R; Remuzzi G; Maschio G; Brenner BM; Kamper A; Zucchelli P; Becker G; Himmelmann A; Bannister K; Landais P; Shahinfar S; de Jong PE; de Zeeuw D; Lau J; Levey AS
Ann Intern Med; 2001 Jul; 135(2):73-87. PubMed ID: 11453706
[TBL] [Abstract][Full Text] [Related]
4. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis.
Jafar TH; Stark PC; Schmid CH; Landa M; Maschio G; de Jong PE; de Zeeuw D; Shahinfar S; Toto R; Levey AS;
Ann Intern Med; 2003 Aug; 139(4):244-52. PubMed ID: 12965979
[TBL] [Abstract][Full Text] [Related]
5. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.
Suzuki H; Kanno Y; Nakamoto H; Okada H; Sugahara S
Clin Exp Hypertens; 2005; 27(2-3):129-38. PubMed ID: 15835375
[TBL] [Abstract][Full Text] [Related]
6. The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis.
Jafar TH; Schmid CH; Stark PC; Toto R; Remuzzi G; Ruggenenti P; Marcantoni C; Becker G; Shahinfar S; De Jong PE; De Zeeuw D; Kamper AL; Strangaard S; Levey AS
Nephrol Dial Transplant; 2003 Oct; 18(10):2047-53. PubMed ID: 13679479
[TBL] [Abstract][Full Text] [Related]
7. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
Vogt L; Kocks MJ; Laverman GD; Navis G
Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
[TBL] [Abstract][Full Text] [Related]
8. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
Lancet; 1997 Jun; 349(9069):1857-63. PubMed ID: 9217756
[TBL] [Abstract][Full Text] [Related]
9. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease.
Matsuda H; Hayashi K; Saruta T
J Hum Hypertens; 2003 Apr; 17(4):271-6. PubMed ID: 12692572
[TBL] [Abstract][Full Text] [Related]
10. Renal protection and antihypertensive drugs: current status.
Salvetti A; Mattei P; Sudano I
Drugs; 1999 May; 57(5):665-93. PubMed ID: 10353294
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade.
Humalda JK; Lambers Heerspink HJ; Kwakernaak AJ; Slagman MC; Waanders F; Vervloet MG; Ter Wee PM; Navis G; de Borst MH;
Am J Kidney Dis; 2015 Feb; 65(2):259-66. PubMed ID: 25278093
[TBL] [Abstract][Full Text] [Related]
12. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
Kanno Y; Takenaka T; Nakamura T; Suzuki H
Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
[TBL] [Abstract][Full Text] [Related]
13. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group.
Giatras I; Lau J; Levey AS
Ann Intern Med; 1997 Sep; 127(5):337-45. PubMed ID: 9273824
[TBL] [Abstract][Full Text] [Related]
14. Impact of angiotensin-converting enzyme gene polymorphism on proteinuria and arterial hypertension.
Zivko M; Kusec R; Galesić K
Coll Antropol; 2013 Sep; 37(3):765-70. PubMed ID: 24308214
[TBL] [Abstract][Full Text] [Related]
15. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials.
Gansevoort RT; Sluiter WJ; Hemmelder MH; de Zeeuw D; de Jong PE
Nephrol Dial Transplant; 1995 Nov; 10(11):1963-74. PubMed ID: 8643149
[TBL] [Abstract][Full Text] [Related]
16. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.
Agarwal R; Siva S; Dunn SR; Sharma K
Am J Kidney Dis; 2002 Mar; 39(3):486-92. PubMed ID: 11877567
[TBL] [Abstract][Full Text] [Related]
17. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).
Ruggenenti P; Perna A; Mosconi L; Pisoni R; Remuzzi G
Kidney Int; 1998 May; 53(5):1209-16. PubMed ID: 9573535
[TBL] [Abstract][Full Text] [Related]
18. Calcium channel blockers in the prevention of end stage renal disease: a review.
Derwa A; Peeters P; Vanholder R
Acta Clin Belg; 2004; 59(1):44-56. PubMed ID: 15065696
[TBL] [Abstract][Full Text] [Related]
19. Add-on angiotensin receptor blockade with maximized ACE inhibition.
Agarwal R
Kidney Int; 2001 Jun; 59(6):2282-9. PubMed ID: 11380832
[TBL] [Abstract][Full Text] [Related]
20. Effect of Lisinopril on the progression of renal insufficiency in mild proteinuric non-diabetic nephropathies.
Cinotti GA; Zucchelli PC;
Nephrol Dial Transplant; 2001 May; 16(5):961-6. PubMed ID: 11328901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
